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Hans-Paul Juretschke2, Claudia Neumann-Häflin2, Hartmut Rütten2 and Michael Böhm1Abstract
Background: The additive effects of obesity and metabolic syndrome on left ventricular (LV) maladaptive
remodeling and function in hypertension are not characterized.
Methods: We compared an obese spontaneously hypertensive rat model (SHR-ob) with lean spontaneously
hypertensive rats (SHR-lean) and normotensive controls (Ctr). LV-function was investigated by cardiac magnetic
resonance imaging and invasive LV-pressure measurements. LV-interstitial fibrosis was quantified and protein levels
of phospholamban (PLB), Serca2a and glucose transporters (GLUT1 and GLUT4) were determined by
immunohistochemistry.
Results: Systolic blood pressure was similar in SHR-lean and SHR-ob (252 ± 7 vs. 242 ± 7 mmHg, p = 0.398) but was
higher when compared to Ctr (155 ± 2 mmHg, p < 0.01 for both). Compared to SHR-lean and Ctr, SHR-ob showed
impaired glucose tolerance and increased body-weight. In SHR-ob, LV-ejection fraction was impaired vs. Ctr
(46.2 ± 1.1 vs. 59.6 ± 1.9%, p = 0.007). LV-enddiastolic pressure was more increased in SHR-ob than in SHR-lean
(21.5 ± 4.1 vs. 5.9 ± 0.81 mmHg, p = 0.0002) when compared to Ctr (4.3 ± 1.1 mmHg, p < 0.0001 for both),
respectively. Increased LV-fibrosis together with increased myocyte diameters and ANF gene expression in SHR-ob
were associated with increased GLUT1-protein levels in SHR-ob suggestive for an upregulation of the GLUT1/ANF-
axis. Serca2a-protein levels were decreased in SHR-lean but not altered in SHR-ob compared to Ctr. PLB-
phosphorylation was not altered.
Conclusion: In addition to hypertension alone, metabolic syndrome and obesity adds to the myocardial phenotype by
aggravating diastolic dysfunction and a progression towards systolic dysfunction. SHR-ob may be a useful model to develop
new interventional and pharmacological treatment strategies for hypertensive heart disease and metabolic disorders.
Keywords: SHR-ob, SHR, MRI, Metabolic syndrome, Hypertension, RemodelingIntroduction
Hypertension, obesity and metabolic syndrome are
highly prevalent cardiovascular diseases and risk factors
in industrialized countries [1]. Type II diabetes and
obesity are common comorbidities in patients with hyper-
tension [2-4] and increase all cause mortality [5-8]. Inter-
estingly, metabolic syndrome amplifies cardiovascular risk
associated with high blood pressure independent of the ef-
fect of several traditional cardiovascular risk factors in
hypertensive subjects [9]. In hypertension, obesity and* Correspondence: dominik.linz@uks.eu
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reproduction in any medium, provided the ormetabolic syndrome frequently coexist and increase the
prevalence of heart failure and in particular heart failure
with preserved ejection fraction and diastolic dysfunction
[10,11].
The aim of the present study was to systematically
characterize maladaptive remodeling processes (functional,
histological and molecular) in an obese spontaneously
hypertensive rat model carrying an additional mutation in
the leptin receptor (SHR-ob) [12] compared tolean spon-
taneously hypertensive rats (SHR-lean) and normotensive
controls (Ctr). The SHR-ob rat is an unique animal model
expressing multiple abnormal phenotypes including obes-
ity, hypertension, hyperinsulinemia and hyperlipidemia
[12]. A detailed characterization of the cardiac phenotype. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Linz et al. Journal of Translational Medicine 2012, 10:187 Page 2 of 10
http://www.translational-medicine.com/content/10/1/187of this rat model is lacking, however, important for future
investigations of therapeutic interventions.
Materials and methods
Animals
Male obese spontaneously hypertensive rats (SHR-ob,
n=8), their heterozygous control littermates (SHR-lean,
n=8) and male normotensive Sprague Dawley (Ctr, n= 10),
were purchased from Charles River Germany GmbH
(Sulzfeld, Germany) at an age of ten weeks. We used
Sprague Dawley rat as the correct and only normotensive
control for SHR-ob rats, as they were developed from a
cross between a SHR-lean and a normotensive Sprague
Dawley rat (Charles River Germany GmbH). However,
Sprague Dawley rat does not represent the most appro-
priate control for the SHR-lean rat. Therefore, some of
the comparisons in this study need to be seen with pre-
caution. The animals were housed individually in stand-
ard cages and received standard chow diet (standard diet
#1320, Altromin, Lage, Germany) and tap water ad libi-
tum. The animal experiments were conducted in accord-
ance with the National Instructions oh Health (NIH)
Guide for the Care and Use of Laboratory Animals and
with the Welfare guidelines and the German law for the
protection of animals. The study was approved by the re-
gional commission on charge in Darmstadt, Germany.
Metabolic characterization was performed at age of
38 weeks. Blood was obtained from the retro-orbital
plexus under light anesthesia (3.5% isoflurane). Blood glu-
cose and glycated hemoglobin (HbA1c) were measured
using standard kits (Cobas Integra, Roche diagnostics,
Mannheim, Germany). An oral glucose tolerance testing
was performed at 38 weeks consisting of glucose measures
at baseline and at 15, 30, 60, 90, 120 and 180 minutes after
oral glucose loading (2 g/kg body weight). Systolic blood
pressure and heart rate were measured by tail cuff method
in conscious rats. At 38 weeks of age, cardiac LV-function
was assessed by cardiac magnetic resonance imaging
(MRI). One week later, invasive LV-pressure measure-
ments were performed and the animals were afterwards
sacrificed.
MRI Acquisition and analysis
At the age of 38 weeks, rats were anesthetized with 1.5-
2.5% isoflurane. Rats were then positioned prone and hori-
zontally in a custom-manufactured animal holder in the
magnet and allowed to breath freely. All experiments were
performed with a Bruker Biospec 70/30 (Bruker Biospin,
Ettlingen, Germany) MRI system, operating at 300MHZ
with a bore of 30 cm. The assembly used consisted of the
gradient system BGA-12S and a rapid-QUAD-Birdcage
(112/90) resonator. Scout images of the individual rat
heart were measured in a coronal (4-chamber-view) and
sagittal (2-chamber-view) orientation. Sixteen contingentslices were acquired in short-axis orientation covering the
entire heart. To cover the cardiac cycle ten time frames for
each slide of the heart were retrospectively reconstructed
with the customized program IntraAngio within the
BrukerVision 5.0 software. For analysis, boundaries of the
LV were obtained in each short-axis image by manual tra-
cing [13]. All dimensions were measured throughout the
cardiac cycle. LV end-diastolic volume (LVedV) and end-
systolic volume (LVesV) were derived from the volume-
time curves for maximal and minimal values. Stroke
volume (SV) and LV-ejection fraction (EF) were subse-
quently computed. Enddiastolic LV-mass was derived from
the sum of the differences between the epicardial (EPI)
and endocardial (ENDO) areas from apex to base,
using the formula: LV-mass =
P
(EPI-ENDO)*(THK+
GAP)*1.05, where THK is the slice thickness, GAP is the
interslice gap, and 1.05 represents the density of myocar-
dial tissue (g/cm3). LV-mass, LVedV and LVesV were nor-
malized on individual tibia length/tibia length of SHR.
Regional myocardial diastolic LV-wall thickness was
assessed automatically in one slice at the level of papillary
muscles. LV-wall was devided in 97 chords.
Cardiac LV-pressure measurements
At age 39 weeks, the animals were anaesthetized with thio-
pental (Narcoren, 100 mg/kg i.p., Merial, Hallbergmoos,
Germany), intubated and lungs were artificially ventilated.
LV-pressures were assessed using a Millar Tip catheter
(Millar Instruments Inc, Houston, USA), which was intro-
duced from the right carotid artery and advanced into the
LV-cavity. Data were digitized with a sampling rate of
1000 Hz and recorded on a PC using specialized software
(HEM, Notocord, Croissy, France). LV peak systolic pres-
sure (LVesP), maximal positive LV-pressure development
(+dP/dtmax), were determined as measurements of systolic
LV-performance. Diastolic LV-functional parameters were:
end diastolic pressure (LVedP), maximal LV-pressure
decay (−dP/dtmax) and the time constant of LV-pressure
decay (Tau), calculated according to Weiss et al. [14]. After
completion of hemodynamic measurements, the animals
were sacrificed by quick excision of the hearts under con-
tinued deep anesthesia. The hearts were arrested in the
diastolic state with intravenous potassium chloride injec-
tion and quickly excised. After rapid excision and careful
removal of atrial and non-cardiac tissue, total heart weight
and LV-heart weight were measured. Aliquots of the tis-
sues were snap-frozen for RNA and protein analysis.
Heart and pancreas tissue analysis
Part of the LV containing the papillary muscles level was
fixed in buffered 4% paraformaldehyde for 24 hours and
embedded in paraffin for histological evaluation. LV sec-
tions at the papillary muscles level were cut at 5 μm,
deparaffinized, rehydrated and stained with Picro-Sirius
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percentage of the LV consisting of interstitial collagen was
calculated as the ratio of Picro-Sirius-Red positively stained
area over total LV tissue area using Morpho Expert image
analysis software (Explora Nova, La Rochelle, France). A
further set of LV sections were additionally stained with
hematoxylin and eosin (H&E). 90–100 cells/animal were
measured to determine cardiomyocyte diameter. Leica
Qwin version 3 morphometry software (Leica, Cambridge,
UK) was used for analysis.
In order to immunohistologically analyze the pancreatic
ß-cell area, pancreas was immersion fixed in buffered 4%
paraformaldehyde, embedded in paraffin, cut at 5 μm and
stained with a Ventana Discovery XT autostainer (Roche
Diagnostics GmbH, Mannheim, Germany) using a mouse
monoclonal anti-insulin antibody (Abcam, ab6995,
Cambridge, UK, 1:1000). The percentage of area stained
for ß-cells was calculated as the ratio of insulin positively
stained area over total pancreatic tissue area using Mor-
pho Expert imaging analysis software (Explora Nova, La
Rochelle, France).
Gene expression and protein level analyses
Reverse Transcription: RNA was prepared from rat LV-
tissues using peqGold TriFast (PeqLab, Erlangen, Germany)
extraction reagent per manufacture′s protocol. For cDNA
preparation 2 μg of RNA were digested with DNAse (Peqlab,
Erlangen) than reverse transcribed using the HighCap cDNA
RT Kit (Applied Biosystems, Darmstadt, Germany) according
to the manufacture′s protocol.
TaqMan PCR: TaqMan PCR was conducted in a StepOne
plus thermocycler (Applied Biosystems, Germany) using
TaqMan GenEx Mastermix (Applied Biosystems, #4369016).
Signals were normalized to corresponding glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) controls. No template
controls were used to monitor for contaminating amplifica-
tions. The ΔCt was used for statistical analysis and 2−ΔΔCt
for data presentation. Probes used to amplify the transcripts
were as follows (purchased by Applied Biosystems): Nppa
(RN00561661_m1); Nppb (Rn00676450_g1); CTGF (Rn005
73960_g1); TGFβ1 (Rn99999016_m1); Col1a (Rn0146384
8_m1); GAPDH (Rn99999916_s1).
Western blot analysis: Rat LV tissue was minced in liquid
nitrogen and resuspended in 5 volumes of homogenization
buffer (in mmol/L): Na2EDTA 5.0, NaF 25.0, sucrose 300.0,
PMSF 1.0, benzamidine 1.0 and KH2PO4 30.0 (pH 7.0) con-
taining complete protease inhibitors (Roche, Germany) and
phosphatase inhibitors (Roche, Germany). The homogenate
was centrifuged at 16.000 g for 20 min. 50 μg of protein
was separated on 8-12% SDS-PAGE and electrophoretically
transferred to nitrocellulose membrane (0.2 μm pore size,
Schleicher and Schuell, Dassel, Germany). Membranes
were blocked in Tris-buffered saline (TBS) containing 5%
nonfat dry milk for 120 min at room temperature andexposed to rabbit polyclonal anti-phospho-phospholamban
Thr17 (sc-17024-R, Santa Cruz Biotechnology, CA,
USA; dilution: 1:400), rabbit polyclonal anti-phospho-
phospholamban Ser16 (#07-052, Upstate, Millipore: di-
lution: 1:400), mouse monoclonal anti-Phospholamban
(#05-205, Millipore: dilution: 1:500), anti-goat polyclonal
Serca2 (N-19, sc-8095, Santa Cruz, 1:1000), anti-mouse
Glut4 (Cell Signaling; #2213S, 1:1000), anti-rabbit Glut1
(Millipore; #07-1401, 1:1000) and mouse monoclonal IgG
GAPDH (6C5: sc-32233, Santa Cruz Biotechnology, 1:5000).
Secondary antibodies goat anti-rabbit (Sigma-Aldrich,
Deisenhofen, Germany; 1:2500), goat anti-mouse (170–6516
Bio-Rad, Germany; 1:2500) and rabbit anti-goat (#172-1034,
Bio Rad, Germany; 1:5000) were incubated for 60 min at
room temperature. Proteins were visualized by enhanced
chemiluminescence according to the manufacturer′s guide-
lines (Amersham Pharmacia Biotech, Freiburg, Germany).
Membrane stripping and re-probing conditions: Mem-
brane was stripped two times for 15 minutes at 56°C using
stripping buffer (62.5 mM Tris–HCl (pH 6.8), 2% SDS.
280 μl of 2-beta mercaptoethanol or a final concentration
of 0.1 M 2-mercaptoethanol), then thoroughly washed
with 1xPBS (in mmol/L: NaCl 170, KCl 33, Na2HPO4 40
and KH2PO4 18, pH 7.2) for at least one hour and blocked
again in Tris-buffered saline (TBS) containing 5% nonfat
dry milk for 120 min at room temperature.
Autoradiographs were quantified by imaging densitom-
etry and analyzed by the “ImageQuant-TM” b Software
(Image Quant, Molecular Dynamics, Krefeld, Germany).
Data are presented as intensity optical density (IOD).
There were no differences between groups in control
genes and proteins.
Statistics
Data are presented as mean ± SEM and differences were
tested for significance using an unpaired Student’s t-test
or 2-way-ANOVA with Bonferroni post-hoc test when




In Figure 1A, phenotypes of SHR-lean and SHR-ob rats
are shown for comparison. At 38 weeks of age, body-
weight index (body-weight normalized on individual tibia
length/tibia length of SHR-ratio) was significantly higher
compared to SHR-lean and Ctr (Figure 1B). Systolic blood
pressure determined by tail cuff in awake rats was similar
in SHR-lean and SHR-ob and significantly increased when
compared with normotensive controls (Figure 1C). Heart
rate did not differ between Ctr, SHR-lean and SHR-ob
(Figure 1D). Wet lung weight did not differ between the
groups (1610± 15 mg in Ctr, 1669± 21 mg in SHR-lean,


































































Figure 1 A) Phenotypes of SHR-lean and SHR-ob rat are shown for comparison. Quantification of B) body-weight index (body-weight
normalized on individual tibia length/tibia length of SHR-ratio), C) systolic blood pressure D) and heart rate determined by tail cuff in controls
(Ctr) (n = 10), SHR-lean (n = 8) and SHR-ob (n = 8) at 38 weeks of age. Data are presented in means ± SEM.
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pensated state of congestion and heart failure.
Metabolic parameters are summarized in Table 1. Fasting
serum insulin levels were significantly elevated in SHR-ob
compared with SHR-lean and Ctr. However, SHR-ob did
not show fasting hyperglycemia and HbA1c was not
increased. SHR-ob showed increased cholesterol and trigly-
ceride blood-levels compared to SHR-lean and controls.
Increased insulin levels in SHR-ob were associated with
increased beta islet cell per total pancreatic area compared
to SHR (Figure 2A). In response to glucose challenge, theTable 1 Metabolic parameters of Ctr, SHR-lean and SHR-ob at
Controls (1) SHR-lean (2)
(n = 10) (n = 8)
Fasting glucose [mmol/L] 6.6 ± 0.2 5.4 ± 0.2
Insulin [μLg/dl] 1.2 ± 0.2 0.91 ± 0.13
HbA1c [%] 4.0 ± 0.1 3.9 ± 0.0
Cholesterol [mmol/L] 1.4 ± 0.1 2.4 ± 0.1
Triglyceride [mmol/L] 1.2 ± 0.2 1.3 ± 0.1
Data are presented in means ± SEM.SHR-ob had a more sustained increase in plasma glucose,
with significantly higher glucose values at 60, 90 and
120 min compared with SHR-lean and controls, indicating
a glucose intolerance in SHR-ob (Figure 2B).
LV-hemodynamics
Cardiac MRI at the age of 38 weeks revealed lower LV-
ejection fraction in SHR-ob rats compared to controls and
SHR-lean (Table 2). Cardiac index was reduced in SHR-ob
compared to Ctr and SHR-lean mainly due to reduced
stroke volume as heart rate did not differ significant between38 weeks of age
SHR-ob (3) p-values
(n = 8) (1) vs. (2) (1) vs. (3) (2) vs. (3)
6.2 ± 0.3 0.0412 0.2231 0.1129
64.3 ± 15.9 0.6692 0.0001 0.0029
4.2 ± 0.2 0.4419 0.3056 0.3702
10.3 ± 1.4 0.0061 0.0001 0.0002











































Figure 2 A) Beta islet cell detection and quantification in pancreatic tissue via insulin immunohistochemistry (pancreatic beta-cell
areas of total pancreatic area) in controls (Ctr), SHR-lean and SHR-ob rats. B) Oral glucose tolerance testing in controls (Ctr) (n = 10), SHR-
lean (n = 7) and SHR-ob (n = 7) for comparison. Data are presented in means ± SEM.
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enddiastolic wall thickness was unchanged (not shown).
During invasive LV-pressure measurement, LVesP was
significantly increased in SHR-lean and SHR-ob com-
pared to controls to a similar extent (178 ± 11 mmHg
and 183 ± 8 mmHg vs. 102 ± 4 mmHg, p < 0.0001 for
both). Indices of diastolic dysfunction (LVedP and Tau,
Figure 3A-B) were significantly higher in SHR-ob com-
pared to normotensive controls and SHR-lean. Maximal
positive LV-pressure development (+dP/dtmax) in all
groups was unchanged. However, maximal pressure decay
during diastole (−dP/dtmax) was impaired in SHR-ob but
unchanged in SHR-lean when compared to normotensive
controls (Figure 3C).
Estimated LV capacitance of SHR-ob was decreased indi-
cated by a leftwards shift of the LVedP/LVedV-diagram and
an increased LVedP/LVedV-ratio due to higher enddiastolic
pressures and moderate increases in enddiastolic volumes
in SHR-ob compared to controls (0.051±0.008 mmHg/μL
in SHR-ob vs. 0.006±0.001 mmHg/μL in Ctr, p < 0.0001).Table 2 LV-function determined by cardiac magnetic resonan
Controls (1) SHR-lean (2)
(n = 10) (n = 8)
Heart rate [1/min] 359± 13 354 ± 8
Ejection fraction [%] 59.6 ± 3.3 54.4 ± 2.4
ED volume index [μL] 636± 26 620 ± 20
ES volume index [μL] 257± 15 282 ± 9
Stroke volume index [μL] 379± 19 338 ± 16
Cardiac index [ml/min] 135± 12 120 ± 8
Data are presented in means ± SEM: LV: left ventricular, bpm: beats per minute; ED:
ED and ES Volume, Stroke volume was normalized on individual tibia length/tibia leEstimated LV capacitance of SHR-lean was not changed
compared to Ctr (0.011±0.003 mmHg/μL, p> 0.05 vs. Ctr).
Cardiac structural-remodeling and differential gene
expression
In SHR-ob, increased LV-mass indices and cardiomyocyte
diameters were associated with up-regulation of BNP and
ANF gene expression (Figure 4A-D). Picro-Sirius Red
staining demonstrated an increase in interstitial collagen
deposition in SHR-lean and in SHR-ob compared to con-
trols (Figure 5A-B). SHR-ob showed the highest amount
of interstitial fibrosis. The papillary muscle was a promin-
ent fibrotic site. In the left ventricle, mRNA levels of col-
lagen1a (Col1a) (Figure 5C), transforming growth factor
beta 1 (TGFβ1) (Figure 5D) and connective tissue growth
factor (CTGF) (Figure 5E) were significantly increased
in SHR-ob compared to controls. By contrast, in SHR-
lean, only Col1a was significantly increased compared
to controls but significantly less pronounced compared
to SHR-ob. TGFβ1 mRNA expression was unchangedce imaging
SHR-ob (3) p-values
(n = 8) (1) vs. (2) (1) vs. (3) (2) vs. (3)
346± 12 0.2722 0.0710 0.1824
46.2 ± 3.9 0.0722 0.0071 0.1824
651± 29 0.0823 0.0629 0.0332
353± 35 0.0487 0.0002 0.0092
298± 22 0.0792 0.0009 0.0029
103± 13 0.3315 0.0021 0.0291
enddiastolic; ES: endsystolic.










































































Figure 3 LV-function determined by invasive LV-measurement procedures: A) Left ventricular enddiastolic pressure (LVedP), B) left
ventricular isovolumetric relaxation time constant (Tau), C) maximal (+dP/dtmax) and minimal (−dP/dtmax) pressure decay in controls

















































































Figure 4 A) Left ventricular mass, normalized on individual tibia length/tibia length of SHR-ratio (LV Mass index), B) cardiomyocyte
diameter, left ventricular gene expression of C) ANF and D) BNP in controls (Ctr), SHR-lean and SHR-ob (n = 6 each). GAPDH was used as
loading control. Data are presented in means ± SEM.













































































Figure 5 A) Representative histological pictures and B) quantification of left ventricular fibrotic area in controls (Ctr), SHR-lean and
SHR-ob. Sirius red was used to stain collagen. Gene expression of C) Col1a, D) TGFβ1 and E) CTGF mRNA in controls (Ctr), SHR-lean and SHR-ob,
normalized to GAPDH expression (n = 6 each). Data are presented in means ± SEM.
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increased in SHR-lean but failed to reach significance.
Proteins involved in Ca2+-handling
Analyses of protein-levels involved in calcium-handling
are shown in Figure 6 and Additional file 1: Figure S1
(Online Supplements). The protein abundance of Serca2a
was significantly reduced in SHR-lean and SHR-ob com-
pared to Ctr. Total phospholamban (PLB) protein was





























Figure 6 A) Representative western blots and B) quantification of Ser
Threonine 17 and Serine 16 in controls (Ctr), SHR-lean and SHR-ob (n
means ± SEM. All remaining western blots are provided as online (Addition(Ser16-PLB) and at threonine 17 (Thr17-PLB) functionally
enhances Serca2a activity and Ca2+ uptake in the SR.
Ser16-PLB to total PLB ratios and Thr17-PLB to total PLB
ratios was not modified in SHR-lean and SHR-ob.
Glucose transporters
GLUT4 protein amount was significantly reduced in
LV-tissue of SHR-lean and SHR-ob compared to con-
trols. In contrast GLUT1 protein amount was signifi-
cantly increased in LV-tissue of SHR-lean and of SHR-ob..3
p=0.4735 p=0.7992 p=0.8012
p=0.1 p=0.5 p=0.3 p=0.4 p=0.2p=0.2
ca2a, total phospholamban (PLB) and its phosphorylation at
= 6-8). GAPDH was used as loading control. Data are presented in
al file 1: Figure S1).
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nounced in SHR-ob compared to SHR-lean (Figure 7).
Discussion
Obese spontaneously hypertensive rats (SHR-ob) exhibit
hyperinsulinemia and demonstrate glucose intolerance in
response to oral glucose load although they were not
overtly diabetic according to fasting glucose and HbA1c-
levels. Identification of a null mutation in the leptin recep-
tor gene in the SHR-ob rats [12] suggests that these ani-
mals exhibit insulin resistance resulting from the absence
of leptin receptors. Additionally, SHR-ob uniformly devel-
oped hyperlipidemia, which was characterized by a marked
rise in plasma triglycerides and plasma cholesterol. The rat
model of SHR-ob is suitable for investigating the add-on
effect of obesity and metabolic syndrome in hypertension
on maladaptive cardiac structural, metabolic and func-
tional remodeling processes. Additionally SHR-ob may be
a useful model to develop new interventional and pharma-
cological treatment strategies for hypertensive heart dis-
ease and metabolic disorders.
Obesity and metabolic syndrome combined with hyper-
tension in SHR-ob but not hypertension alone in SHR-
lean resulted in a moderate decrease in LV-systolic func-
tion when compared to normotensive controls but LV-
systolic global contractility was preserved as indicated by
LV-pressure measurements. Reduced maximal pressure
decay during diastole together with increased LVedP,
increased Tau and decreased LV- capacitance (increased
LVedP/LVedV-ratio) suggest the development of diastolic
dysfunction in SHR-ob. Therefore the combination of
obesity and hypertension in SHR-ob aggravates dia-
stolic dysfunction and a progression towards systolic dys-
function compared to hypertension alone in SHR-lean. In
accordance with this finding, the combination of hyper-
tension, obesity and metabolic syndrome increases preva-























Figure 7 A) Representative western blots and B) quantification of glu
SHR-ob (n = 6 each). GAPDH was used as a loading control. Data are prespreserved ejection fraction (diastolic dysfunction) and has
been identified as a relevant risk factor for heart failure in
humans [10,11].
Hearts of SHR-ob showed increased cardiomyocyte
diameters and increased LV mass index. Additionally,
increased enddiastolic LV volume together with un-
changed enddiastolic wall thickness suggests cardiac
hypertrophy. Cellular hypertrophy was associated with
increased LV ANF-gene expression in SHR-ob reflecting
the effect of increased afterload in this model [15]. Car-
diac hypertrophy due to long-standing arterial hyperten-
sion is associated with a high incidence of heart failure
in humans [16].
Metabolic syndrome and obesity combined with
hypertension in SHR-ob resulted in increased interstitial
collagen deposition compared to hypertension alone in
SHR. Increased expression of Col1a suggests that altera-
tions in the rate of collagen synthesis are responsible for
increased fibrosis in SHR-ob. TGFβ1 has been reported
to be involved in fibroblast proliferation and extracellu-
lar matrix deposition. Gene expression of TGFβ1 and
CTGF was elevated in SHR-ob but not in SHR-lean and
may be contributory to the subsequent pronounced car-
diac fibrosis in SHR-ob [17]. CTGF is induced by TGFβ1
in connective tissue cells and may represent a down-
stream mediator of TGFβ1-activity [18]. Increased colla-
gen deposition may be a relevant factor in the observed
development of diastolic dysfunction in SHR-ob [19].
Impaired LV-relaxation has been related to diastolic Ca2+
overload and consequently prolonged interaction of myofi-
laments in hypertensive cardiomyopathy [20,21]. The pre-
dominant alteration in Ca2+ homeostasis is a decreased
uptake of Ca2+ into the sarcoplasmic reticulum (SR)
due to decreased Serca2a protein levels [22]. Decreased Ser-
ca2a protein levels occur already at the stage of mild-
to-moderate cardiac hypertrophy, precedes LV-dysfunction









cose transporters Glut4 and Glut1 in controls (Ctr), SHR-lean and
ented in means ± SEM.
Linz et al. Journal of Translational Medicine 2012, 10:187 Page 9 of 10
http://www.translational-medicine.com/content/10/1/187[20]. In the present study, a reduction in Serca2a protein
level was observed in hypertrophied LV myocardium of
SHR-lean and SHR-ob. This may mediate reduced SR Ca2+
stores and slow Ca2+ transient decay. The reduction in the
expression of cardiac Serca2a in SHR-lean and SHR-ob was
accompanied by the development of diastolic dysfunction.
PLB phosphorylation by protein kinase A (PKA) at serine
16 (Ser16-PLB) and by CaMKII at threonine 17 (Thr17-
PLB) functionally enhances Serca2a Ca2+ uptake. However,
Ser16-PLB to total PLB ratios and Thr17-PLB to total PLB
were not significantly modified in SHR-lean and SHR-ob.
This suggests that metabolic syndrome at the background
of hypertension and hypertension alone causes a reduction
in Serca2a protein levels, which may play a role for the de-
velopment of diastolic dysfunction in SHR-lean and SHR-
ob rats. Increased interstitial fibrosis amount and possibly
also changes in different proteins involved in cardiac myo-
cyte relaxation (e.g. titin) could account for the more pro-
nounced diastolic dysfunction in SHR-ob compared to
SHR-lean.
In SHR-ob, cardiac protein expression of GLUT1 was
increased compared to SHR-lean and normotensive con-
trols. During euglycemic hyperinsulinemia, the insulin in-
dependent glucose transporter GLUT1 is a major mediator
of basal cardiac glucose uptake [23,24]. In diabetes and
hypertension [25], there is profound downregulation of
GLUT4. A lower GLUT4 content in hypertrophied hearts
was associated with cardiac insulin resistance [25] but not
with a reduction in basal glucose uptake [26] as deletion of
GLUT4 is associated with induction of GLUT1 expression
[27] compensating for the loss of function of GLUT4.
Interestingly, fetal hearts have less GLUT4 and more
GLUT1 than adult hearts [28]. Increased GLUT1 expres-
sion together with the induction of natriuretic peptide gene
expression as one of the most conserved features of ven-
tricular hypertrophy in SHR-ob suggests an upregulation
of GLUT1/ANF-axis being in agreement with the concept
of re-expression of fetal genes in cardiac hypertrophy. A
comparable activation of the GLUT1/ANF-axis has already
been described in pure diabetic [23] and hypertensive
[24,25] rat models with cardiac hypertrophy.
The more pronounced structural and metabolic
changes together with changes in proteins involved in
calcium handling observed in our study may provide a
sufficient explanation for the observed add-on effect of
metabolic syndrome and obesity in hypertension on ag-
gravation of diastolic dysfunction and a progression to-
wards systolic dysfunction in SHR-ob compared to SHR-
lean. Our findings in SHR-ob are in line with other rat
models of hypertension combined with obesity and/or
metabolic syndrome mainly characterized by cardiac
hypertrophy and increased cardiac fibrosis [29,30]. This
is the first report characterizing cardiac function and re-
modeling in SHR-ob rats.Conclusion and perspectives
We describe a rat model for maladaptive cardiac remod-
eling in obesity and metabolic syndrome associated with
hypertension, a common comorbid condition, gaining
increasing relevance. Obesity combined with hyperten-
sion further aggravates maladaptive remodeling leading
to diastolic dysfunction and a progression towards sys-
tolic dysfunction mainly by a pronounced increase in
LV-fibrosis, cellular hypertrophy and moderate changes
in proteins involved in Ca2+-handling. Myocardial hyper-
trophy in obese hypertensive rats are associated with an
increased upregulation of the cardiac GLUT1/ANF-axis.
SHR-ob may be a useful model to further elucidate patho-
physiological alterations to develop new interventional
and pharmacological treatment strategies for hypertensive
heart disease and metabolic disorders.Additional file
Additional file 1: Figure S1. Western Blots analyses of protein
expression involved in calcium handling. Western Blot analysis of Serca2a,
total phospholamban (PLB) and its phosphorylation at Threonine 17
(Thr17) and Serine 16 (Ser 16) of controls (Ctr), SHR-lean and SHR-ob
(n=6-8). GAPDH was used as loading control. In all experiments, Ctr, SHR-
lean and SHR-ob tissues were compared by western blot analysis at the
same time with identical conditions and separated on the same SDS-
PAGE. Detection of phospholamban phosphorylation at Ser16 or Thr17
were performed on two separate gels as indicated. Membranes were
stripped afterwards and analysed for total phospholamban and GAPDH
as loading control. Background color of autoradiographs depended on
different exposure times resulting from respective endogenous protein
expression and concentration.
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